8-K: Shattuck Labs Reports Q1 2026 Results, Clinical Milestones

Shattuck Labs announced Q1 2026 financial results, highlighting the completion of Phase 1 enrollment for SL-325 and providing an updated cash runway into 2029.

Summary

• Shattuck Labs reported its financial results for the first quarter ended March 31, 2026.
• Enrollment for the Phase 1 clinical trial of SL-325 has been completed, with data expected in Q2 2026.
• A Phase 2 clinical trial for SL-325 in Crohn's disease patients is anticipated to begin in Q3 2026.
• The company's lead bispecific antibody candidate has entered IND-enabling activities.
• As of March 31, 2026, Shattuck Labs had $90.4 million in cash and cash equivalents and investments.
• Research and development expenses were $10.9 million for Q1 2026.
• General and administrative expenses were $4.6 million for Q1 2026.
• The net loss for Q1 2026 was $14.8 million, or $0.13 per share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with key clinical trial milestones achieved and a strong cash position, though the company continues to operate at a net loss.

Positives

• Completion of enrollment in the Phase 1 clinical trial for SL-325, a key step towards data release.
• Projected data release for the SL-325 Phase 1 trial in Q2 2026, providing crucial safety and efficacy insights.
• Anticipated initiation of a Phase 2 trial for SL-325 in Crohn's disease patients in Q3 2026, advancing the pipeline.
• Lead bispecific antibody candidate entering IND-enabling activities, indicating pipeline progression.
• Extended cash runway into 2029, assuming full exercise of outstanding common stock warrants, providing financial stability.
• Increase in cash and cash equivalents and investments to $90.4 million as of March 31, 2026, from $60.9 million in the prior year.

Negatives

• Net loss of $14.8 million for the quarter ended March 31, 2026.
• Net loss per share of $0.13 for the quarter, compared to $0.27 in the prior year, though the per-share loss is lower due to increased share count.
• Increased R&D expenses to $10.9 million from $9.9 million in the prior year, reflecting ongoing development costs.
• Slight increase in G&A expenses to $4.6 million from $4.5 million in the prior year.

Risks

• The unpredictable relationship between preclinical study results and clinical study results.
• The timing or likelihood of regulatory filings and approvals.
• Global macroeconomic conditions and related volatility.
• Potential for additional costs associated with clinical development activities.
• Risks and uncertainties identified in Shattuck's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025.

Future Outlook

Shattuck Labs expects to present data from its Phase 1 SL-325 trial in Q2 2026 and initiate a Phase 2 trial in Crohn's disease patients in Q3 2026. The company anticipates its current cash resources will fund operations into 2029, assuming full warrant exercise.

Management Comments

• "We are pleased to have completed enrollment in our Phase 1 clinical trial of SL-325, and are looking forward to sharing a comprehensive data set on all single ascending dose and multiple ascending dose cohorts from this study in the second quarter of 2026, including safety and tolerability, pharmacokinetics, receptor occupancy, duration of receptor occupancy, pharmacodynamics, and immunogenicity data," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
• Management will participate in one-on-one meetings at the Leerink Partners Therapeutics Forum 2026.

Industry Context

StockSavvy.ai notes that Shattuck Labs' focus on DR3 blocking antibodies for inflammatory and immune-mediated diseases aligns with a growing trend in biotechnology to develop targeted therapies for complex conditions. The company's progress in its SL-325 program and development of bispecific antibodies positions it within a competitive but promising segment of the pharmaceutical industry.

Stakeholder Impact

• Shareholders: The extended cash runway into 2029 provides financial stability, reducing immediate dilution concerns, while progress in clinical trials offers potential for future value creation.
• Employees: Continued R&D investment and pipeline progression suggest ongoing employment opportunities and company growth.
• Creditors: The company's substantial cash reserves indicate a strong ability to meet its financial obligations.

Next Steps

• Present safety and tolerability, PK, receptor occupancy, duration of receptor occupancy, pharmacodynamics, and immunogenicity data from the Phase 1 SL-325 trial in Q2 2026.
• Disclose targets, supporting preclinical data, and expected development timelines for the lead bispecific antibody candidate in Q2 2026.
• Initiate a Phase 2 clinical trial of SL-325 in patients with Crohn's disease in Q3 2026, subject to positive Phase 1 data and regulatory alignment.
• Participate in one-on-one meetings at the Leerink Partners Therapeutics Forum 2026 on July 14-15, 2026.

Key Dates

Recommendation

The company is making steady progress in its clinical development programs, particularly with SL-325, and maintains a healthy cash position. However, without definitive Phase 1 data or further de-risking events, a 'hold' recommendation is appropriate for seasoned investors, awaiting more concrete clinical outcomes before considering a stronger position.

Keywords

Shattuck Labs, SL-325, DR3 blocking antibody, Crohn's disease, Phase 1 trial, Phase 2 trial, biotechnology, clinical-stage